Anti-Hypertensive Drugs - Lebanon

Lebanon

Highlights

in Lebanon, a country in the Middle East, is expected to witness significant growth in the Anti-Hypertensive Drugs market.
By 2024, the revenue in this market is projected to reach US$5.27m.
This growth is anticipated to continue at a Compound Annual Growth Rate (CAGR) of -1.32% between 2024 and 2029, resulting in a market volume of US$4.93m by 2029.
When compared globally, United States is anticipated to generate the highest revenue in the Anti-Hypertensive Drugs market.
In 2024, United States is expected to generate revenue of US$12.29bn.
Lebanon's anti-hypertensive drug market is witnessing a surge in demand due to the increasing prevalence of hypertension among the population.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The demand for anti-hypertensive drugs in Lebanon has been on the rise in recent years.

Customer preferences: Patients in Lebanon are increasingly seeking medical help for hypertension, leading to a rise in the demand for anti-hypertensive drugs. This trend is driven by the growing awareness of the importance of preventive healthcare and the increasing prevalence of hypertension among the population.

Trends in the market: The anti-hypertensive drugs market in Lebanon is dominated by a few major players who offer a wide range of products to meet the needs of patients. The market is characterized by intense competition among these players, leading to frequent product launches and aggressive marketing strategies. In recent years, there has been a shift towards combination therapies, which offer greater convenience and better outcomes for patients.

Local special circumstances: The healthcare system in Lebanon is characterized by a large number of private hospitals and clinics, which provide high-quality care to patients. However, the cost of healthcare in Lebanon is relatively high, which can be a barrier to access for some patients. The government has implemented a number of measures to address this issue, including the introduction of a national health insurance scheme.

Underlying macroeconomic factors: The Lebanese economy has been facing significant challenges in recent years, including political instability and a high level of public debt. These factors have contributed to a slowdown in economic growth and a decline in consumer confidence. However, the healthcare sector has remained relatively resilient, driven by the growing demand for healthcare services and the increasing prevalence of chronic diseases such as hypertension.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.